A new era for aortic regurgitation: how new guidelines and dedicated devices for AR will redefine treatment
Sponsored by JenaValve Technology
TAVI
Symposium
JenaValve Technology
The Forum
Watch this session if you want
To understand how the new ESC guidelines will refine the diagnosis and optimise the treatment of aortic regurgitation (AR) and help improve patient care of this undertreated disease
To learn about and observe cases featuring the JenaValve Trilogy System, the only CE Mark-approved device for treating both severe aortic regurgitation and aortic stenosis
To see real-world, never before presented data on the Trilogy System in Europe
Welcome and session objectives
Dan Blackman
Case presentation: pure AR with no calcium
Mohammad Alkhalil
How do the new ESC guidelines address the management of pure AR?
Hendrik Treede
Contemporary treatment of aortic regurgitation
Discussion and audience interaction
Case presentation: AR in complex anatomy
Mohammad Alkhalil
Challenging anatomy
Discussion and audience interaction
ALIGN-AR data and Trilogy teal-world data
Matti Adam
Session evaluation and key learnings
Martine Gilard
